In last trading session, Citius Pharmaceuticals Inc (NASDAQ:CTXR) saw 0.49 million shares changing hands with its beta currently measuring 1.38. Company’s recent per share price level of $0.77 trading at $0.01 or 1.16% at ring of the bell on the day assigns it a market valuation of $122.78M. That closing price of CTXR’s stock is at a discount of -122.08% from its 52-week high price of $1.71 and is indicating a premium of 22.08% from its 52-week low price of $0.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.44 million shares which gives us an average trading volume of 644.91K if we extend that period to 3-months.
For Citius Pharmaceuticals Inc (CTXR), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.02 in the current quarter.
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Upright in the green during last session for gaining 1.16%, in the last five days CTXR remained trading in the green while hitting it’s week-highest on Tuesday, 11/14/23 when the stock touched $0.77 price level, adding 2.52% to its value on the day. Citius Pharmaceuticals Inc’s shares saw a change of -2.16% in year-to-date performance and have moved 0.38% in past 5-day. Citius Pharmaceuticals Inc (NASDAQ:CTXR) showed a performance of 9.55% in past 30-days. Number of shares sold short was 16.89 million shares which calculate 25.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $8.00 to the stock, which implies a rise of 90.38% to its current value. Analysts have been projecting $8.00 as a low price target for the stock while placing it at a high target of $8.00. It follows that stock’s current price would drop -938.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -938.96% for stock’s current value.
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
Statistics highlight that Citius Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -34.50% of value to its shares in past 6 months, showing an annual growth rate of 13.04% while that of industry is 10.50. Apart from that, the company came raising its revenue forecast for fiscal year 2023.
And 1 analysts are in estimates of company making revenue of $9.85 million in the next quarter that will end on Dec 2023.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.36% during past 5 years.
Citius Pharmaceuticals Inc is more likely to be releasing its next quarterly report between December 20 and December 26 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Insiders are in possession of 7.75% of company’s total shares while institution are holding 10.67 percent of that, with stock having share float percentage of 11.57%. Investors also watch the number of corporate investors in a company very closely, which is 10.67% institutions for Citius Pharmaceuticals Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at CTXR for having 8.08 million shares of worth $9.7 million. And as of Jun 29, 2023, it was holding 5.09% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 6.68 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 4.21% of outstanding shares, having a total worth of $8.02 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 4.0 million shares of worth $4.8 million or 2.52% of the total outstanding shares. The later fund manager was in possession of 2.76 million shares on Aug 30, 2023, making its stake of worth around $2.52 million in the company or a holder of 1.74% of company’s stock.